Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021

Rhea-AI Summary

Radius Health (Nasdaq: RDUS) will announce its fourth quarter financial results on February 25, 2021, followed by a conference call at 8:30 a.m. ET. The call will provide insights into the company’s performance and future prospects. Investors can listen to the live audio webcast on the company’s website, and a replay will be available later that day. Radius focuses on innovative endocrine therapeutics, with its lead product TYMLOS (abaloparatide) approved for osteoporosis treatment. The company is also advancing several investigational drugs in its pipeline.

Positive

• Upcoming fourth quarter earnings report may indicate potential growth metrics.
• Lead product TYMLOS is FDA approved, supporting revenue potential.

Negative

• None.

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Domestic Dial-In Number: (866) 323-7965
International Dial-In Number: (346) 406-0961
Conference ID: 8266586

A replay of the conference call will be available on February 25 at 11:30 a.m. ET and live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 8266586. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor & Media Relations Contact:
Peter Schwartzman
Email: investor-relations@radiuspharm.com 
Phone: (617) 583-2017

FAQ

When will Radius Health release its fourth quarter earnings?

Radius Health will release its fourth quarter financial results on February 25, 2021.

What time is the Radius Health conference call on February 25, 2021?

The conference call will take place at 8:30 a.m. ET.

How can I access the Radius Health earnings call replay?

The replay will be available on February 25, 2021, at 11:30 a.m. ET by dialing (855) 859-2056 for U.S. callers or (404) 537-3406 for international callers.

What is Radius Health's lead product?

Radius Health's lead product is TYMLOS (abaloparatide), which is approved for treating postmenopausal women with osteoporosis.

What is the focus of Radius Health's clinical pipeline?

Radius Health's clinical pipeline includes investigational products for osteoporosis treatments and therapies for hormone-receptor positive breast cancer and other endocrine-related diseases.